Last reviewed 2026-04-20 · How we verify

Carrisyn (ACEMANNAN)

Phase 2 active Oligosaccharide

Carrisyn (generic name: ACEMANNAN) is a drug. It is currently in Phase 2 development.

Carrisyn works by interacting with a specific molecular target to produce a therapeutic effect.

Carrisyn, also known as ACEMANNAN, is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The current owner of Carrisyn is not publicly disclosed.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ACEMANNAN
Modality	Oligosaccharide
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Carrisyn is a key that fits into those locks. When it binds to the lock, it triggers a series of events that can help treat a particular disease or condition. This is a simplified explanation of how small molecules like Carrisyn work at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carrisyn CI brief — competitive landscape report
Carrisyn updates RSS · CI watch RSS

Frequently asked questions about Carrisyn

What is Carrisyn?

Carrisyn (ACEMANNAN) is a Oligosaccharide drug.

How does Carrisyn work?

Carrisyn works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Carrisyn?

ACEMANNAN is the generic (nonproprietary) name of Carrisyn.

What development phase is Carrisyn in?

Carrisyn is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing